EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

23 January 2025
EMA/CAT/25914/2025
Human Medicines Division

Committee for Advanced Therapies (CAT)

Draft agenda for the meeting on 22-24 January 2025

Chair: Ilona Reischl; Vice-Chair: Kieran Breen

22 January 2025, 14:00 – 18:30, room 2C

23 January 2025, 09:00 – 18:30, room 2C

24 January 2025, 09:00 – 13:00, room 2C

Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, this agenda is a working document primarily designed for CAT members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CAT plenary session to be held 22-24 January 2025. See January 2025 CAT minutes (to be published post February 2025 CAT meeting).

1.2. Adoption of agenda

CAT agenda for 22-24 January 2025 meeting

1.3. Adoption of the minutes

CAT minutes for 04-06 December 2024 meeting

2. Evaluation of ATMPs

2.1. Opinions

No items

2.2. Oral explanations

No items

2.3. Day 180 list of outstanding issues

No items

2.4. Day 120 list of questions

No items

2.5. Day 80 assessment reports

No items

2.6. Update on ongoing initial applications

No items

2.7. New applications

2.7.1. Nadofaragene firadenovec - EMEA/H/C/005856

Treatment of adult patients with high-grade (HG), Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC)

Scope: Timetable for assessment

Action: for adoption

2.7.2. Autologous CD34+ haematopoietic stem cells transduced ex vivo with a lentiviral vector encoding human Wiskott-Aldrich syndrome protein - Orphan - EMEA/H/C/006525

Fondazione Telethon Ets; Treatment of patients with Wiskott-Aldrich Syndrome (WAS)

Scope: Timetable for assessment

Action: for adoption

2.8. Withdrawal of initial marketing authorisation application

No items

2.9. Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004

No items

2.10. GMP and GCP inspections requests

No items

2.11. Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

2.11.1. Breyanzi - Lisocabtagene maraleucel / Lisocabtagene maraleucel - EMEA/H/C/004731/II/0043/G

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Concetta Quintarelli; PRAC Rapporteur: Gabriele Maurer

Scope: Safety & quality, opinion

Extension of indication for Breyanzi to include treatment of adult patients with 3rd line + follicular lymphoma (FL) based on final results from the pivotal study JCAR017-FOL-001 (FOL-001, TRANSCEND-FL). This is a phase 2, open-label, single-arm, multicohort, multicentre study to evaluate efficacy and safety of JCAR017 in adult subjects with relapsed or refractory (r/r) follicular Lymphoma (FL) or marginal zone lymphoma (MZL). As a

consequence, sections 4.1, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 5.0 of the RMP is being submitted. Furthermore, as part of the application the MAH is requesting a 1-year extension of the market protection.

Action: for adoption

Request for supplementary information adopted on 08.11.2024.

2.11.2. CARVYKTI - Ciltacabtagene autoleucel - Orphan - EMEA/H/C/005095/II/0034

Janssen-Cilag International NV

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Jo Robays

Scope: Safety, request of supplementary information

Submission of an updated RMP version 5.2 in order to add a new important identified risk of "Secondary malignancy of T-cell origin", to change the important potential risk of "Second primary malignancies" to "Second primary malignancy except secondary malignancy of T-cell origin", and to include an additional pharmacovigilance activity for testing of secondary malignancies of T-cell origin, following the PRAC recommendation for the Secondary malignancy of T-cell origin signal (EPITT no: 20040).

Action: for adoption

2.11.3. CARVYKTI - Ciltacabtagene autoleucel - Orphan - EMEA/H/C/005095/II/0035

Janssen-Cilag International NV

Rapporteur: Jan Mueller-Berghaus

Scope: Quality, opinion

Action: for adoption

2.11.4. Imlygic - Talimogene laherparepvec - EMEA/H/C/002771/II/0068

Amgen Europe B.V.

Rapporteur: Maija Tarkkanen

Scope: Quality, opinion

Action: for adoption

2.11.5. Kymriah - Tisagenlecleucel - Orphan - EMEA/H/C/004090/II/0092

Novartis Europharm Limited

Rapporteur: Rune Kjeken, PRAC Rapporteur: Gabriele Maurer

Scope: Safety, request of supplementary information

Update of section 4.2 of the SmPC in order to update the 'monitoring after infusion' recommendations, based on existing clinical trial data as well as literature references

reporting real world experience. The Package Leaflet is updated accordingly. The RMP version 8.0 has also been submitted. In addition, the MAH took the opportunity to introduce a minor change to the HCP educational programme in the Annex II in order to enhance readability.

Action: for adoption

2.11.6. Strimvelis - Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence - Orphan - EMEA/H/C/003854/II/0040

Fondazione Telethon ETS

Rapporteur: Sol Ruiz, PRAC Rapporteur: Liana Martirosyan

Scope: Safety, opinion

Submission of an updated RMP version 7.0 in order to propose amendments to the STRIM-005 and STRIM-003 study protocols, as well as revised timelines for completion of both studies. In addition, the Annex II is updated accordingly.

Action: for adoption

Request for supplementary information adopted on 13.09.2024.

2.11.7. Zolgensma - Onasemnogene abeparvovec - Orphan - EMEA/H/C/004750/II/0055

Novartis Europharm Limited

Rapporteur: Emmely de Vries

Scope: Quality, opinion

Action: for adoption

2.11.8. Tecartus; Yescarta - Axicabtagene ciloleucel; Brexucabtagene autoleucel - Orphan - EMEA/H/C/WS2771

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Karin Erneholm

Scope: Safety, request for supplementary information

Submission of an updated RMP version 4.3 for Tecartus and version 11.1 for Yescarta following the PRAC recommendation for the Secondary malignancy of T-cell origin signal (EPITT no: 20040), and of a PASS protocol for a framework for the sampling and testing of secondary malignancies of T-cell origin

Action: for adoption

2.12. Extension applications

No items

2.13. Other Post-Authorisation Activities

2.13.1. Breyanzi - Lisocabtagene maraleucel / Lisocabtagene maraleucel - EMEA/H/C/004731/REC/022.1

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Concetta Quintarelli

Scope: Quality, opinion

Action: for adoption

2.13.2. CARVYKTI - Ciltacabtagene autoleucel - Orphan - EMEA/H/C/005095/MEA/007.3

Janssen-Cilag International NV

Rapporteur: Jan Mueller-Berghaus

Scope: Pharmacovigilance, opinion

Protocol amendment / PASS study PCSONCA0014(v. 1)
Post-authorisation Safety Study Survey to Evaluate the Effectiveness of the Ciltacabtagene Autoleucel HCP Educational Program and the Product Handling Training.

Action: for adoption

2.13.3. CARVYKTI - Ciltacabtagene autoleucel - Orphan - EMEA/H/C/005095/REC/018

Janssen-Cilag International NV

Rapporteur: Jan Mueller-Berghaus

Scope: Quality

Action: for adoption

2.13.4. CARVYKTI - Ciltacabtagene autoleucel - Orphan - EMEA/H/C/005095/PSA/S/0116

Janssen-Cilag International NV

Rapporteur: Jan Mueller-Berghaus

Scope: PASS protocol (PRAC led procedure)

An updated protocol (Amendment 2) for study 68284528MMY4004 An Observational Post-authorization Safety Study to Evaluate the Safety of Multiple Myeloma Patients Treated with Ciltacabtagene Autoleucel

Action: for information

2.13.5. BEQVEZ - Fidanacogene elaparvovec - Orphan - EMEA/H/C/004774/ANX/003

Pfizer Europe MA EEIG

Rapporteur: Jan Mueller-Berghaus

Scope: PAES protocol

Protocol for PAES C0371007: in order to further characterise the long-term efficacy and safety of Beqvez in adults with severe and moderately severe haemophilia B (congenital factor IX deficiency) without a history of factor IX inhibitors and without detectable antibodies to variant AAV serotype Rh74, the MAH should conduct and submit the final results of registry based study C0371007, according to an agreed protocol.

Action: for adoption

2.13.6. Ebvallo - Tabelecleucel - Orphan - EMEA/H/C/004577/REC/008

Pierre Fabre Medicament

Rapporteur: Egbert Flory

Scope: Quality, opinion

Action: for adoption

2.14. Companion diagnostics - initial consultation

No items

2.15. Companion diagnostics – Follow-up consultation

No items

3. Certification of ATMPs

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Opinion

3.2. Day 60 Evaluation Reports

No items

3.3. New Applications

4. Scientific Recommendation on Classification of ATMPs

4.1. New requests – Appointment of CAT Coordinator

4.2. Day 30 ATMP scientific recommendation

4.2.1. mRNAs encoding IL-12 and IL-18

Treatment of gastric cancer

Scope: ATMP scientific recommendation

Action: for adoption

4.2.2. BCMA targeting Chimeric Antigen Receptor expressing mRNA transfected autologous T cells

Treatment of Myasthenia Gravis

Scope: ATMP scientific recommendation

Action: for adoption

4.2.3. Autologous Tumor Infiltrating Lymphocytes (TILs)

Treatment of adult patients with advanced or 2/4 metastatic solid tumors who have not responded to standard therapies (chemotherapy, radiation therapy, molecule-targeted therapy) or are ineligible for alternative treatment options or in associated treatment with chemotherapy in multimodel therapy

Scope: ATMP scientific recommendation

Action: for adoption

4.2.4. Adeno-associated virus serotype 5 containing the human RORA gene (AAV5-hRORA)

Treatment of adult and paediatric patients with vision loss due to Geographic Atrophy secondary to dry age-related macular degeneration and Stargardt Disease

Scope: ATMP scientific recommendation

Action: for adoption

4.3. Day 60 revised scientific recommendation (following list of questions)

No items

4.4. Finalisation of procedure

4.4.1. Autologous primary urothelial cells expanded

For use of cystoplasty/orthotopic neobladder

Scope: European Commission raised no comments. ATMP scientific recommendation

Action: for adoption

4.4.2. Adeno-associated virus serotype 5 containing the human NR2E3 gene (AAV5-hNR2E3)

Treatment of adult and paediatric patients with vision loss due to inherited retinal dystrophy, specifically retinitis pigmentosa or Leber congenital amaurosis, and who have sufficient viable retinal cells

Scope: European Commission raised no comments. ATMP scientific recommendation

Action: for adoption

4.5. Follow-up and guidance

No items

5. Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. New requests - appointment of CAT Rapporteurs

5.1.1. Ongoing scientific advice procedures - Appointment of CAT Peer Reviewers

Timetable:

- Start of procedure at SAWP:	13-16.01.2025
- Appointment of CAT Peer Reviewers:	22-24.01.2025
- SAWP first reports:	03.02.2025
- CAT Peer Reviewer comments (NC/C):	07.02.2025
- CAT Peer Reviewer comments (Q):	12.02.2025
- Discussion at SAWP:	10-13.02.2025
- Discussion at CAT and feedback to SAWP:	19-21.02.2025

5.1.2. Scientific advice procedures starting at the next SAWP meeting

Timetable:

- Start of procedure at SAWP:	10-13.02.2025
- Appointment of CAT Peer Reviewers:	19-21.02.2025
- SAWP first reports:	03.03.2025
- CAT Peer Reviewer comments (NC/C):	07.03.2025

- CAT Peer Reviewer comments (Q): 12.03.2025
- Discussion at SAWP: 10-13.03.2025
- Discussion at CAT and feedback to SAWP: 19-21.2025

No items

5.2. Procedures discussed at SAWP – 1st reports, D40 JRs, LoIs

5.3. Finalisation of D70 procedures – feedback from the discussion meeting

5.4. Final Advice Letters for procedures finalised the previous month

6. Pre-Authorisation Activities

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Paediatric investigation plans

No items

6.2. ITF briefing meetings in the field of ATMPs

6.3. Priority Medicines (PRIME) – Eligibility requests

6.3.1. Month 0 - Start of the procedure

Timetable for assessment:

Procedure start:	13-16.01.2025
SAWP recommendation:	13.02.2025
CAT recommendation:	21.02.2025
CHMP adoption of report and final recommendation:	27.02.2025

6.3.2. Month 1 – Discussion of eligibility

6.3.3. Month 2 – Recommendation of eligibility

6.3.4. Ongoing support

No items

7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the CAT

7.1.1. CAT membership

Action: for information

7.1.2. Vote by proxy

Action: for information

7.1.3. CAT Strategic Review & Learning meeting (SRLM) under the Polish presidency

CAT: Dariusz Sladowski

Scope: Preparation for the meeting

Action: for information

7.1.4. CAT Strategic Review & Learning meeting (SRLM) under the Danish presidency

CAT: Martin Bronislaw Oleksiewicz

Scope: Preparation for the meeting

Action: for information

7.1.5. DG SANTE exchange of views with CAT on EMA committee reform

Scope: Exchange of views with European Commission on Pharmaceutical Legislation Reform

Action: for discussion

7.2. Coordination with EMA Scientific Committees

7.2.1. Revision of the procedural advice on CHMP/CAT/PRAC Rapporteur/Co-Rapporteur appointment principles

Scope: Revision of the procedural advice on CHMP/CAT/PRAC Rapporteur/Co-Rapporteur appointment principles, objective criteria and methodology in accordance with Article 62(1) of Regulation (EC) No 726/2004.

Action: for information

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

7.3.1. Revision of ATMP GMP guideline

Scope: Presentation of the main changes for the revision of the GMP ATMP guideline and next steps

Action: for information

7.3.2. Q and A on decentralised manufacturing

Scope: Update on comments received

Action: for discussion

7.3.3. Update on Quality Innovation Group (QIG) activities

CAT: Marcel Hoefnagel, Marcos Timon

Scope: Update the CAT on recent relevant activities of the QIG and inform the CAT members on how to access the QIG documents.

Action: for information

7.4. Cooperation with the EU regulatory network

7.4.1. EU Network Training Centre: supporting capacity and capability building in the EU Medicines Regulatory Network

Scope: Advancing the ATMP training curriculum going forward

Action: for information

7.4.2. Feedback from HTA/EMA workshop on uncertainty management

Scope: Oral report from workshop on uncertainty management

Action: for information

7.5. Cooperation with international regulators

7.5.1. ATMP cluster teleconference with US-FDA, Health Canada and PMDA (Japan)

CAT: Ilona Reischl

Scope: Feedback from the teleconference of 12.12.2024

Action: for information

7.5.2. US-FDA-EMA collaboration on gene therapies for (ultra) rare diseases (CoGenT)

Scope: Feedback on the CoGenT pilot project

Action: for information

7.6. CAT work plan

7.6.1. CAT work plan 2025

CAT: Ilona Reischl

Scope: CAT work plan 2025

Action: for adoption

7.7. Planning and reporting

7.7.1. Business Pipeline Report – Q4-24 Forecast report

Scope: Q4/2024 Update of the MAAs expected in 2025, report for the human scientific committees

Action: for information

7.8. Others

7.8.1. IRIS functionalities for CAT members post-authorisation procedure management transition to IRIS

Scope: The IRIS team will provide a demo of the IRIS Network portal functionalities useful to CAT members following the transition of post-authorisation procedures to IRIS which took place in January 2025

Action: for information

8. Any other business

No items

Date of next CAT meeting:

19-21 February 2025

9. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

For a list of acronyms and abbreviations, see:

List of abbreviations used in EMA human medicines scientific committees and CMDh documents, and in relation to EMA's regulatory activities

Evaluation of ATMPs (section 2)

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists Post-authorisation activities (section 2.11-2.13) and any ATMP related inspection requests (section 2.14).

New applications (sections 2.1. to 2.9.)

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found here.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a **Day 120 list of questions** (section 2.4) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (**Ongoing evaluation procedures** (section 2.3). Section 2.6 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

Oral explanation (section 2.2.)

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.

Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

New applications (section 2.7.)

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.

Withdrawal of applications (section 2.8.)

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.9.)

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

GMP and GCP Inspections Issues (section 2.14.)

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Post-authorisation activities (section 2.11-2.13.)

Section 2.11 lists type II variations, including extension of indication applications and re-examination procedures for type II variations for which the applicant has requested re-examination of the opinion previously issued by the CHMP. Section 2.12 list extension application according to Annex I of Reg. 1234/2008 and section 2.13 includes all other post-authorisation activities concerning authorised ATMPs that are not covered elsewhere in the agenda such as post-authorisation measures, annual reassessments, 5-year renewals, supply shortages, qualify defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

Companion diagnostics (section 2.14-2.15)

This section lists applications for initial and follow-on consultation of companion diagnostics.

Certification of ATMPs (section 3)

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found here.

Scientific Recommendation on Classification of ATMPs (Section 4)

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found here.

Scientific Advice (section 5)

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found here.

Pre-Authorisation (section 6)

Paediatric Investigation Plan (PIP)

This section includes the discussion of an ATMP before a formal application for marketing authorisation is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

ITF Briefing meeting in the field of ATMPs

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found here.

Priority Medicines (PRIME)

This section includes the new requests for eligibility to PRIME for ATMPs under development, the discussions in CAT of these eligibility requests and the final recommendations for eligibility of ATMPs adopted by CHMP.

CAT will appoint one of its members as the CAT sponsor for each new ATMP eligibility request who will lead the CAT discussion based on the recommendation from the SAWP.

Organisational, regulatory and methodological matters (section 7)

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

Any other business (section 8)

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/